title: New prescription drug labeling regulations and the demise of "the letter".
authors.affiliation: Dr. Witkop is with Preventive Medicine and Obstetrics and Gynecology at the United States Air Force Academy, Colorado Springs, Colorado, and she is Assistant Professor, Obstetrics and Gynecology, at the Uniformed Services University of the Health Sciences, Bethesda, Maryland; e-mail: katika@aya.yale.edu.
authors.forename: Catherine Takacs
authors.initials: CT
authors.lastname: Witkop
mesh_terms: D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control; D005260:Female; D006801:Humans; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D055553:Prescription Drugs; D011358:Product Surveillance, Postmarketing; D014481:United States
chemical_list: D055553:Prescription Drugs
references.citation: Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398–407.
references.citation: Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998;338:1128–37.
references.citation: Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551–66.
references.citation: Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes [published erratum appears in N Engl J Med 2008;359:106]. N Engl J Med 2008;358:2003–15.